Aarohan Pruthi Clinical Oncology Society of Australia Annual Scientific Meeting 2024

Abstracts this author is presenting:

• Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC — Afternoon Tea, Exhibition & Poster Session 1
• Intracranial Outcomes of 1L Selpercatinib in Advanced RET Fusion-positive (RET+) NSCLC: LIBRETTO-431 Study — Afternoon Tea, Exhibition & Poster Session 1
• Health-related Quality of Life (HRQoL) and Symptoms in LIBRETTO-431 Patients with RET Fusion-positive Advanced Non-Small-Cell Lung Cancer (NSCLC) — Afternoon Tea, Exhibition & Poster Session 1
• Efficacy of Selpercatinib by RET Fusion Partner in RET+ NSCLC: Results from the LIBRETTO-001 and LIBRETTO-431 Trials — Afternoon Tea, Exhibition & Poster Session 1
• Dose Adjustments and Exposure-Response Associated With Selpercatinib in Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) — Afternoon Tea, Exhibition & Poster Session 1